Initial report touted positive exploratory results for nelotanserin, but a correction wiped out optimism.
Publication of negative results of Phase 3 idalopirdine trials lays to rest yet another candidate drug.
An anti-Aβ antibody holding a transferrin ticket to the brain stokes an immune response against Aβ, but not against the transport system.
Microglia-like cells from blood monocytes facilitate large-scale studies.
Screen identifies antibody that induces mouse bone marrow cells to differentiate and travel to the brain, where they clear plaques.
Pancreatic cancer felled the man who led groundbreaking research on astrocytes, oligodendrocytes, and microglia.
The Alzforum team compiles some of their favorite stories from the past year.
Bayesian adaptive Phase 2 trial of anti-protofibril Aβ antibody did not, as desired, deliver an accelerated result. It will now continue to its end at 18 months.
At SfN 2017, some of the lesser-known tau toxicities came in for deep scrutiny.
At SfN 2017, scientists advanced the idea that bacteria teeming in a person’s digestive tract could influence both pathology and symptoms of diseases such as Alzheimer’s.
Why, hello tau! Convergence of PET and EEG research affirms that sleeping well is crucial to memory consolidation and curbing Alzheimer’s-related proteins.
Tau Snapshots from Neuroscience 2017 Disturbed Sleep Exerts Toll on Memory and Neurodegeneration Gut Microbiome May Modify Neurodegeneration This year’s annual meeting drew more than 23,000 scientists and featured 1,000 presentations on Alzheimer’s ...
Novel ways to control tau captured the imaginations of scientists at the Society for Neuroscience annual meeting.
Using CRISPR for the first time in a model of ALS, researchers dampened expression of mutant SOD1 in mouse motor neurons
Protein bundles released by microglia, called ASC specks, seed Aβ aggregates in vitro and in vivo.